Liver Organoids

Developmental Biology & Differentiation

The development of liver organoids from human induced pluripotent stem cells (iPSCs) involves mimicking the complex signaling cascades that direct embryonic hepatogenesis. During development, the liver arises from the ventral foregut endoderm, where signaling from adjacent cardiac mesoderm (FGFs) and septum transversum mesenchyme (BMPs) specifies the hepatic lineage, forming the hepatic diverticulum.

To replicate this in vitro, stem cells are first driven to a definitive endoderm fate using Activin A and Wnt3a. Second, exposure to BMP4 and FGF2 specifies the endoderm toward a hepatic fate, generating hepatoblasts (bipotent liver progenitor cells).

These hepatoblasts can differentiate into either hepatocytes (the primary parenchymal cells of the liver) or cholangiocytes (biliary epithelial cells).

To achieve high functional maturity, the cells are co-cultured with supportive non-parenchymal cells, including human umbilical vein endothelial cells (HUVECs) and mesenchymal stem cells (MSCs). In 3D suspension or Matrigel droplets, these cell types self-assemble into vascularized hepatic buds. The MSCs provide structural support and secrete extracellular matrix, while the endothelial cells organize into early capillary-like networks, facilitating nutrient diffusion and oxygenation.

Lobular Architecture & Cellular Diversity

Mature liver organoids display a multicellular architecture that mimics the cellular diversity and layout of the human liver lobule. A single organoid contains hepatocytes, cholangiocytes, Kupffer cells (resident liver macrophages), and hepatic stellate cells.

The hepatocytes express high levels of mature functional markers, including albumin (ALB), alpha-1 antitrypsin (A1AT), and Cytochrome P450 enzymes. These cells organize into cords, establishing polarized cell membranes with distinct basolateral (facing the sinusoids) and apical (facing the bile canaliculi) domains.

The cholangiocytes form functional, hollow bile canaliculi networks. These networks express Cytokeratin 19 (CK19) and the multi-drug resistance protein (MDR1) transporter, actively exporting biliary salts and metabolic wastes into the canalicular lumen.

Kupffer cells, which reside within the organoid structure, maintain their immunological functions. They respond to inflammatory signals (like lipopolysaccharides) by secreting cytokines (TNF-alpha, IL-6), providing a model for studying drug-induced liver injury (DILI) and inflammatory liver diseases.

Stellate cells, when exposed to chronic toxic stimuli, transition from a quiescent, vitamin A-storing state to an activated, myofibroblast-like state. They secrete collagen, replicating the early cellular events of liver fibrosis and cirrhosis in vitro.

Pharmacological Applications and Metabolic Profiling

The primary utility of liver organoids in drug discovery is their capacity for human-specific drug clearance and metabolic profiling. The human liver is the primary organ responsible for xenobiotic metabolism, converting lipophilic drugs into hydrophilic metabolites for renal excretion.

These constructs include hepatocytes, Kupffer cells, and endothelial cells. They self-assemble to mimic liver lobules, facilitating realistic drug clearance and toxicity profiling in preclinical laboratory environments.

Hepatocytes in liver organoids express active Phase I and Phase II metabolic enzymes:

• Phase I (Cytochrome P450): Active CYP3A4, CYP2D6, CYP2C9, and CYP1A2 enzymes catalyze oxidation, reduction, and hydrolysis reactions. The activity of these enzymes is quantified using fluorometric substrate assays or mass spectrometry.
• Phase II (Conjugation): UDP-glucuronosyltransferases (UGTs) and sulfotransferases (SUTs) conjugate Phase I metabolites with glucuronic acid or sulfate, rendering them water-soluble.

Because they maintain cytochrome activity for months (unlike primary human hepatocytes in 2D culture, which lose metabolic activity within 48 hours), liver organoids allow long-term toxicity screening. This is critical for predicting drug-induced liver injury (DILI) caused by chronic dosing.

Additionally, liver organoids can model metabolic diseases, such as non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH). By exposing organoids to high concentrations of free fatty acids (oleic and palmitic acids), researchers can induce lipid accumulation (steatosis) and evaluate the efficacy of therapeutic candidates in reversing fat accumulation and subsequent fibrotic signaling.